Immune cell therapy for advanced pulmonary fibrosis
Part of Lungs & breathing clinical trials.
This trial tests a new immune-based therapy called CAR-DC for people with advanced IPF whose disease is still getting worse despite standard treatments. It aims to slow down or stop the scarring in the lungs, offering a new option for those who are not getting a lung transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old and have a confirmed diagnosis of idiopathic pulmonary fibrosis (IPF).
- Your lung function must be getting worse even though you've tried standard treatments like pirfenidone or nintedanib.
- You must meet at least one criterion that would make you eligible for a lung transplant (such as a significant drop in lung function or low oxygen levels) but you have chosen not to have a transplant.
- You cannot have had cellular immunotherapy (like CAR-T) in the last 3 months, and you must have adequate blood counts.
- You must not have had a sudden flare-up of IPF in the last 4 weeks, and you cannot have any other type of lung disease.
- You must not have a history of cancer (except certain cured skin cancers), severe kidney failure, bleeding problems, or be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell-based therapy for people with IPF, a lung condition that causes scarring and breathing problems. The goal is to see if the treatment can help slow the disease and improve breathing ability.
This trial tests whether a new treatment made from menstrual blood stem cells, given by injection, can help people with IPF, a condition that causes lung scarring and makes breathing harder. The study aims to see if the treatment can slow down the disease and improve lung function.
This trial is testing a new medication called HSK50042 to see if it can help people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. If you have IPF and meet some basic health criteria, you might be able to join.
This trial tests a new drug called BC006 for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. The goal is to see if it can help improve lung function. You may be eligible if you are 40 or older and have a confirmed IPF diagnosis with specific lung test results.
This trial tests a new medicine called AK3280 to see if it can help people with idiopathic pulmonary fibrosis (a lung disease that causes scarring). It aims to slow down the worsening of lung function. If you have IPF and haven't been treated with anti-fibrotic drugs recently, you might be able to join.
This trial tests a new inhaled therapy made from tiny particles derived from placental cells, which may help reduce scarring in the lungs. It is a phase 1 study, so the main goal is to check safety and see if the treatment has any effect on IPF.
Hear when a new Idiopathic Pulmonary Fibrosis(IPF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.